Lacutoclax+Rocbrutinib

Preclinical

GGuangzhou Lupeng Pharmaceutical Company LTD.

Lacutoclax+Rocbrutinib is one of 9 therapeutic programs targeting Mantle Cell Lymphoma (MCL). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Mantle Cell Lymphoma (MCL)Recruiting

Mantle Cell Lymphoma (MCL)Preclinical

Recruiting

Competition

Competitive Landscape

8 competitors in Mantle Cell Lymphoma (MCL)

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 2

3 2

Rituxan

Roche

Phase 2

2 3

Calquence

AstraZeneca

Phase 2

2 4

Jaypirca

Eli Lilly

Phase 2

1 5

Gazyva

Roche

Phase 2

1 6

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

2 7

Lisaftoclax

Ascentage Pharma Group Inc.

Phase 2

2 8

ACP-196

AAcerta Pharma BV

Phase 2

1 9

Lacutoclax+Rocbrutinib

GGuangzhou Lupeng Pharmaceutical Company LTD.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2033

PreclinicalRecruiting

Mantle Cell Lymphoma (MCL)

NCT07609862

Clinical

Trials by Indication[1]

Mantle Cell Lymphoma (MCL)1 trial

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTK Inhibitor Rocbrutinib in Combination With BCL-2 Inhibitor Lacutoclax in Patients With B-Cell Malignancies

Recruiting·GGuangzhou Lupeng Pharmaceutical Company LTD.·Preclinical·NCT07609862·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lacutoclax+Rocbrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lacutoclax+Rocbrutinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Guangzhou Lupeng Pharmaceutical Company LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GGuangzhou Lupeng Pharmaceutical Company LTD.

Lacutoclax+Rocbrutinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2033

Trials by Indication[1]

Mantle Cell Lymphoma (MCL)1 trial

References

Drug Info

Quick Facts

Related News